ArticleScientific reports2025
Impact of mild hyperthermia on tumor-immune dynamics explored through mathematical modeling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational Oncology of Chemotaxis-Driven Tumour-Immune Spatial Patterning and Stability.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune system plays a vital role in cancer control, yet its efficacy is often compromised by tumor-induced immunosuppression. Moderate hyperthermia ([Formula: see text]C) can enhance immune responses and improve therapeutic outcomes. This work investigates how mild hyperthermia modulates tumor-immune dynamics through a mathematical modeling approach. Specifically, we analyze how heat-induced reduction in tumor proliferation and enhancement of immune recruitment affect tumor control outcomes. We extend the Kuznetsov model of tumor-immune interactions by incorporating thermal effects on two key parameters: tumor growth rate and immune cell recruitment rate. A bifurcation analysis is performed to characterize how the system's equilibrium structure changes as these parameters vary. Our analysis shows that the tumor-immune system has critical points where small changes in tumor growth or immune response can dramatically alter outcomes. Moderate hyperthermia can shift these tipping points in favor of the immune system, making it more likely that the tumor is controlled rather than escapes immune surveillance. In practical terms, hyperthermia expands the conditions under which immune-mediated tumor suppression is successful and reduces the scenarios that would lead to tumor progression, effectively improving the chances of therapeutic control. These results provide quantitative insight into how transient hyperthermia can reshape tumor-immune dynamics, increasing the likelihood of immune-mediated tumor suppression. The model suggests that moderate hyperthermia, by simultaneously reducing tumor proliferation and enhancing immune recruitment, can shift tumor-immune interactions toward control in a subset of initial conditions. Thus, it offers a theoretical framework supporting the use of hyperthermia as an immunomodulatory adjuvant in cancer therapy, particularly in combination with immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.